Literature DB >> 501488

Potentiation of neuromuscular weakness in infant botulism by aminoglycosides.

C L'Hommedieu, R Stough, L Brown, R Kettrick, R Polin.   

Abstract

A retrospective study of ten patients with infant botulism who received gentamicin or kanamycin suggests that aminoglycoside antibiotics potentiate muscular weakness and precipitate respiratory failure as late as 27 days after onset of the disease. Although it is difficult to separate progression of the disease from the effects of antibiotics, the rapidity of deterioration following aminoglycoside treatment and the rapidity of recovery following cessation of aminoglycoside therapy is highly suggestive. A review of five patients who received only penicillin or a semisynthetic derivative of penicillin did not reveal any temporal deterioration with onset of penicillin therapy or improvement with cessation of penicillin therapy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 501488     DOI: 10.1016/s0022-3476(79)80314-5

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

Review 1.  Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review.

Authors:  Todd A Linsenmeyer
Journal:  J Spinal Cord Med       Date:  2013-09       Impact factor: 1.985

2.  Constipation and poor feeding in an infant with botulism.

Authors:  Kevin L Schwartz; John W Austin; Michelle Science
Journal:  CMAJ       Date:  2012-09-17       Impact factor: 8.262

Review 3.  Botulinum toxin. From poison to medicine.

Authors:  L E Davis
Journal:  West J Med       Date:  1993-01

4.  Two cases of type A infant botulism in Grenoble, France: no honey for infants.

Authors:  Gautier Hoarau; Isabelle Pelloux; Armelle Gayot; Isabelle Wroblewski; Michel-Robert Popoff; Christelle Mazuet; Max Maurin; Jacques Croizé
Journal:  Eur J Pediatr       Date:  2011-12-10       Impact factor: 3.183

5.  Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021.

Authors:  Agam K Rao; Jeremy Sobel; Kevin Chatham-Stephens; Carolina Luquez
Journal:  MMWR Recomm Rep       Date:  2021-05-07

6.  Antimicrobial Susceptibility of 260 Clostridium botulinum Type A, B, Ba, and Bf Strains and a Neurotoxigenic Clostridium baratii Type F Strain Isolated from California Infant Botulism Patients.

Authors:  Jason R Barash; Joe B Castles; Stephen S Arnon
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

Review 7.  Neurological manifestations and toxicities of the antituberculosis drugs. A review.

Authors:  M R Holdiness
Journal:  Med Toxicol       Date:  1987 Jan-Feb

8.  Acute toxicity of aminoglycoside antibiotics as an aid in detecting botulism.

Authors:  Y C Wang; D H Burr; G J Korthals; H Sugiyama
Journal:  Appl Environ Microbiol       Date:  1984-11       Impact factor: 4.792

9.  Quantitation of Clostridium botulinum organisms and toxin in the feces of an infant with botulism.

Authors:  J C Paton; A J Lawrence; J I Manson
Journal:  J Clin Microbiol       Date:  1982-01       Impact factor: 5.948

10.  Survival of a Foal with Type A Botulism.

Authors:  J S W Prutton; K G Magdesian; A Plummer; D C Williams; M Aleman
Journal:  J Vet Intern Med       Date:  2016-02-19       Impact factor: 3.333

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.